AU2004312530A1 - Pyrrole and pyrazole DAAO inhibitors - Google Patents

Pyrrole and pyrazole DAAO inhibitors Download PDF

Info

Publication number
AU2004312530A1
AU2004312530A1 AU2004312530A AU2004312530A AU2004312530A1 AU 2004312530 A1 AU2004312530 A1 AU 2004312530A1 AU 2004312530 A AU2004312530 A AU 2004312530A AU 2004312530 A AU2004312530 A AU 2004312530A AU 2004312530 A1 AU2004312530 A1 AU 2004312530A1
Authority
AU
Australia
Prior art keywords
carboxylic acid
ppm
mhz
hydrogen
pyrrole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004312530A
Other languages
English (en)
Inventor
Milan Chytil
Q. Kevin Fang
Michele Heffernan
Seth Hopkins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AU2004312530A1 publication Critical patent/AU2004312530A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/16—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
AU2004312530A 2003-12-29 2004-12-28 Pyrrole and pyrazole DAAO inhibitors Abandoned AU2004312530A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53297903P 2003-12-29 2003-12-29
US60/532,979 2003-12-29
PCT/US2004/043791 WO2005066135A2 (en) 2003-12-29 2004-12-28 Pyrrole and pyrazole daao inhibitors

Publications (1)

Publication Number Publication Date
AU2004312530A1 true AU2004312530A1 (en) 2005-07-21

Family

ID=34748837

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004312530A Abandoned AU2004312530A1 (en) 2003-12-29 2004-12-28 Pyrrole and pyrazole DAAO inhibitors

Country Status (15)

Country Link
US (4) US7488747B2 (https=)
EP (1) EP1709004A2 (https=)
JP (1) JP2007517056A (https=)
KR (1) KR20060128976A (https=)
CN (1) CN1922149A (https=)
AU (1) AU2004312530A1 (https=)
BR (1) BRPI0418244A (https=)
CA (1) CA2551952A1 (https=)
CZ (1) CZ2006427A3 (https=)
IL (2) IL176606A0 (https=)
NZ (1) NZ548212A (https=)
PL (1) PL380887A1 (https=)
RU (3) RU2361862C2 (https=)
WO (1) WO2005066135A2 (https=)
ZA (1) ZA200605383B (https=)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2501134A1 (en) * 2002-10-10 2004-04-22 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia
WO2005011677A1 (en) * 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. 5-substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the nicotinic acid receptor rup25 for the treatment of dyslipidemia and related diseases
AU2004312530A1 (en) 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
JP2009500425A (ja) 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
BRPI0706365A2 (pt) 2006-01-06 2011-03-22 Sepracor Inc Cicloalquilaminas como inibidores da recaptação de monoamina
NZ569608A (en) 2006-01-06 2011-09-30 Sepracor Inc Tetralone-based monoamine reuptake inhibitors
DK2816024T3 (en) 2006-03-31 2017-10-30 Sunovion Pharmaceuticals Inc CHIRALE AMINER
EP2057162A2 (en) * 2006-06-30 2009-05-13 Sepracor Inc. Fused heterocyclic inhibitors of d-amino acid oxidase
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
US7579370B2 (en) 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
US20080082066A1 (en) * 2006-10-02 2008-04-03 Weyerhaeuser Co. Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks
DE102006060598A1 (de) * 2006-12-21 2008-06-26 Merck Patent Gmbh Tetrahydrobenzoisoxazole
US20090099248A1 (en) * 2007-01-18 2009-04-16 Sepracor Inc. Inhibitors of d-amino acid oxidase
US7902252B2 (en) * 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
AU2008229265A1 (en) * 2007-03-21 2008-09-25 Janssen Pharmaceutica N.V. Method for treating CB2 receptor mediated pain
AU2008259841B2 (en) 2007-05-31 2015-02-05 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
TWI435875B (zh) * 2008-07-08 2014-05-01 Daiichi Sankyo Co Ltd 含氮芳香族雜環化合物
WO2010017418A1 (en) * 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
GB0817379D0 (en) * 2008-09-23 2008-10-29 Merck Sharp & Dohme New use
IT1394400B1 (it) * 2009-02-25 2012-06-15 Neuroscienze Pharmaness S C Ar L Composizioni farmaceutiche
IT1393930B1 (it) 2009-02-25 2012-05-17 Neuroscienze Pharmaness S C A R L Composti farmaceutici
WO2011017634A2 (en) * 2009-08-07 2011-02-10 Sepracore Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase
EP2526095A1 (en) 2010-01-19 2012-11-28 Theravance, Inc. Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents
US10387135B2 (en) * 2010-11-05 2019-08-20 FedEx Supply Chain Logistics & Electronics, Inc. System and method for remotely flashing a wireless device
WO2012078817A1 (en) 2010-12-08 2012-06-14 Vanderbilt University Bicyclic pyrazole compounds as allosteric modulators of mglur5 receptors
US20120202856A1 (en) 2011-02-07 2012-08-09 Player Mark R Substituted benzimdazole derivatives useful as trpm8 receptor modulators
CA2839735A1 (en) * 2011-06-17 2012-12-20 Yong-xin LI D-serine for the treatment of visual system disorders
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
AU2012337781B2 (en) 2011-11-15 2017-07-06 Takeda Pharmaceutical Company Limited Dihydroxy aromatic heterocyclic compound
WO2014025993A1 (en) 2012-08-08 2014-02-13 The Johns Hopkins University Inhibitors of d-amino acid oxidase
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
GB201222711D0 (en) * 2012-12-17 2013-01-30 Takeda Pharmaceutical Novel compounds
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
CN103274984B (zh) * 2013-06-03 2016-08-24 四川铂瑞生物医药有限公司 一种5-甲基-吡咯-2甲酸乙酯的制备方法
US12383518B2 (en) 2013-11-03 2025-08-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Disulfide-masked pro-chelator compositions and methods of use
US11504346B2 (en) 2013-11-03 2022-11-22 Arizona Board Of Regents On Behalf Of The University Of Arizona Redox-activated pro-chelators
US9339482B2 (en) 2013-11-22 2016-05-17 Regents Of The University Of Minnesota Methods to treat dysregulated blood glucose disorders
US10336724B2 (en) * 2017-10-18 2019-07-02 Syneurx International (Taiwan) Corp. D-amino acid oxidase inhibitors and therapeutic uses thereof
US11753400B2 (en) 2017-10-18 2023-09-12 Syneurx International (Taiwan) Corp. D-amino acid oxidase inhibitors and therapeutic uses thereof
CN108546266B (zh) * 2018-07-25 2020-09-22 上海毕得医药科技有限公司 一种1,4,6,7-四氢吡喃[4,3-c]吡唑-3-羧酸的合成方法
CN111116446B (zh) * 2020-01-14 2023-07-14 成都师范学院 一种3-取代-1h-吡咯的合成工艺方法
MY197760A (en) 2020-06-01 2023-07-13 Celagenex Res India Pvt Ltd Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE616646A (https=)
DE1124485B (de) 1960-02-12 1962-03-01 Hoechst Ag Verfahren zur Herstellung von analeptisch wirksamen Phenylcycloalkylmethylaminen
JPS6033106B2 (ja) 1977-10-07 1985-08-01 住友化学工業株式会社 カルボン酸エステル、その製造法およびそれを有効成分とする殺虫、殺ダニ剤
ZA817261B (en) 1980-10-23 1982-09-29 Schering Corp Carboxyalkyl dipeptides,processes for their production and pharmaceutical compositions containing them
US4540690A (en) 1982-02-09 1985-09-10 The Upjohn Company 2-(Phenylmethylene)cycloalkylamines and -azetidines
JPS58177915A (ja) 1982-04-12 1983-10-18 Green Cross Corp:The 抗血栓剤
JPS61502818A (ja) 1984-07-30 1986-12-04 シェリング・コ−ポレ−ション シス、エンド−オクタヒドロシクロペンタ〔ｂ〕ピロ−ル−２−カルボキシレ−トの新規製造方法
DE3431541A1 (de) 1984-08-28 1986-03-06 Hoechst Ag, 6230 Frankfurt Cis,endo-2-azabicycloalkan-3-carbonsaeure-derivate, verfahren zu deren herstellung, deren verwendung sowie zwischenprodukte bei deren herstellung
US4738709A (en) 1985-01-10 1988-04-19 Ppg Industries, Inc. Herbicidally active substituted benzisoxazoles
US4751231A (en) 1987-09-16 1988-06-14 Merck & Co., Inc. Substituted thieno[2,3-b]pyrrole-5-sulfonamides as antiglaucoma agents
JPH01172388A (ja) 1987-12-25 1989-07-07 Sumitomo Chem Co Ltd チエノ〔３，２−ｂ〕ピロロ〔２，３−ｄ〕ピロール類およびその製法
US4981870A (en) 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US4960786A (en) 1989-04-24 1990-10-02 Merrell Dow Pharmaceuticals Inc. Excitatory amino acid antagonists
JPH0347123A (ja) 1989-05-05 1991-02-28 G D Searle & Co インドール―２―カルボキシレート化合物類を含有するｃｎｓ疾患治療用組成物
US5137910A (en) 1989-05-05 1992-08-11 C.D. Searle & Co. Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders
KR100195656B1 (ko) 1989-05-31 1999-06-15 로버트 에이.아미테이지 치료학적으로 유용한 2-아미노테트랄린 유도체
US5086054A (en) 1990-07-31 1992-02-04 Sri International Novel arylcycloalkanepolyalkylamines
US5284862A (en) 1991-03-18 1994-02-08 Warner-Lambert Company Derivatives of 2-carboxyindoles having pharmaceutical activity
GB9208492D0 (en) 1992-04-16 1992-06-03 Glaxo Spa Heterocyclic compounds
WO1993022299A1 (en) * 1992-04-24 1993-11-11 E.I. Du Pont De Nemours And Company Fungicidal oxazolidinones
CA2146755A1 (en) 1992-10-28 1994-05-11 Kenji Takeda Novel 1,2-benzoisoxazole derivative or its salt and brain-protecting agent comprising the same
GB9304500D0 (en) 1993-03-05 1993-04-21 Glaxo Spa Heterocyclic compounds
ES2081747B1 (es) 1993-09-07 1997-01-16 Esteve Labor Dr Amidas derivadas de tienopirroles, su preparacion y su aplicacion como medicamentos.
GB9321221D0 (en) 1993-10-14 1993-12-01 Glaxo Spa Heterocyclic compounds
CN1047384C (zh) 1994-07-28 1999-12-15 北京大学 雷米普利的合成方法
ES2208690T3 (es) 1994-08-30 2004-06-16 Sankyo Company Limited Isoxazol.
US5484763A (en) 1995-02-10 1996-01-16 American Cyanamid Company Substituted benzisoxazole and benzisothiazole herbicidal agents
GB9502695D0 (en) 1995-02-11 1995-03-29 Glaxo Spa Pharmaceutical composition
CA2217707A1 (en) 1995-04-10 1996-10-17 Fujisawa Pharmaceutial Co., Ltd. Indole derivatives as cgmp-pde inhibitors
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
US5859042A (en) * 1995-09-27 1999-01-12 Ono Pharmaceutical Co., Ltd. Five membered heterocyclic compounds
AU7073296A (en) * 1996-05-01 1997-11-19 Eli Lilly And Company 5,6,7,8-tetrahydropyrido{2,3-d}pyrimidines
FR2753098B1 (fr) 1996-09-06 1998-11-27 Sod Conseils Rech Applic Composition pharmaceutique comprenant au moins un inhibiteur de no synthase et au moins un piegeur des formes reactives de l'oxygene
US5922752A (en) 1997-06-11 1999-07-13 Hoechst Marion Roussell, Inc. NMDA (n-methyl-d-aspartate) antagonists
GB9803228D0 (en) 1998-02-17 1998-04-08 Zeneca Ltd Chemical compounds
US6476078B2 (en) 1999-08-11 2002-11-05 Sepracor, Inc. Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US6632836B1 (en) 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
FR2789079B3 (fr) * 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
US6828460B2 (en) 1999-03-22 2004-12-07 Pfizer Inc. Resorcinol derivatives
FR2795733B1 (fr) 1999-06-30 2001-09-07 Aventis Pharma Sa Derives de streptogramines, leur preparation et les compositions qui les contiennent
AU6462500A (en) 1999-07-29 2001-02-19 Patrick T. Prendergast Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
ATE257480T1 (de) 1999-09-30 2004-01-15 Pfizer Prod Inc Bicyclische pyrrolylamide als glycogenphosphorylase-inhibitoren
EP1391460A1 (en) 1999-09-30 2004-02-25 Pfizer Products Inc. Tricyclic pyrrolyl amides as glycogen phosphorylase inhibitors
HU230030B1 (hu) 1999-10-08 2015-05-28 Debiopharm International Sa Fab I inhibitorok
US6528254B1 (en) 1999-10-29 2003-03-04 Stratagene Methods for detection of a target nucleic acid sequence
SE9903998D0 (sv) 1999-11-03 1999-11-03 Astra Ab New compounds
JP2001247462A (ja) 2000-03-07 2001-09-11 Otsuka Pharmaceut Co Ltd ウレアーゼ阻害剤
US6632417B2 (en) 2000-03-07 2003-10-14 Chevron U.S.A. Inc. Process for preparing zeolites
EP1136071A3 (en) 2000-03-22 2003-03-26 Pfizer Products Inc. Use of glycogen phosphorylase inhibitors
US6632948B2 (en) 2000-04-19 2003-10-14 Kaneka Corporation Azetidine derivative and process for preparation thereof
GB0012214D0 (en) 2000-05-19 2000-07-12 Merck Sharp & Dohme Therapeutic agents
WO2002012249A2 (en) 2000-08-04 2002-02-14 Eli Lilly And Company Substituted pyrrole compounds and their use as spla2 inhibitors
GB0021831D0 (en) 2000-09-06 2000-10-18 Astrazeneca Ab Chemical compounds
WO2002031128A1 (en) 2000-10-06 2002-04-18 Smithkline Beecham Corporation Methods of agonizing and antagonizing fabk
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
DE10063992A1 (de) 2000-12-21 2002-07-04 Max Planck Gesellschaft Tryptophan-Analoga in Proteinen, Peptiden und peptidischen Leitstrukturen
US6372919B1 (en) 2001-01-11 2002-04-16 Dov Pharmaceutical, Inc. (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as an anti-depressant agent
EP1412515A2 (en) 2001-01-16 2004-04-28 Genset Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase antagonists
US20020123490A1 (en) 2001-03-01 2002-09-05 Pfizer Inc. Combination treatment for anxiety, depression, obsessive compulsive disorder and psychosis
WO2003000657A1 (en) 2001-06-20 2003-01-03 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
US6603000B2 (en) 2001-07-11 2003-08-05 Boehringer Ingelheim Pharmaceuticals, Inc. Synthesis for heteroarylamine compounds
AU2002328596B2 (en) 2001-08-09 2007-09-20 Daiichi Pharmaceutical Co., Ltd. Diamine derivatives
US7045543B2 (en) 2001-11-05 2006-05-16 Enzrel Inc. Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites
US20030162825A1 (en) 2001-11-09 2003-08-28 Sepracor Inc. D-amino acid oxidase inhibitors for learning and memory
WO2003048113A1 (en) 2001-11-30 2003-06-12 Sepracor Inc. Tramadol analogs and uses thereof
TW200307539A (en) 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
US6995144B2 (en) 2002-03-14 2006-02-07 Eisai Co., Ltd. Nitrogen containing heterocyclic compounds and medicines containing the same
WO2003091213A1 (en) 2002-04-25 2003-11-06 Yamanouchi Pharmaceutical Co., Ltd. Novel amide derivatives or salts thereof
CA2484582A1 (en) 2002-05-03 2003-11-13 Warner-Lambert Company Llc Bombesin antagonists
JP4459051B2 (ja) 2002-07-31 2010-04-28 メルシャン株式会社 新規生理活性物質
EP1543011B1 (en) 2002-09-06 2006-05-03 Janssen Pharmaceutica N.V. Thienopyrrolyl and furanopyrrolyl compounds and their use as histamine h4 receptor ligands
WO2004024130A2 (en) 2002-09-16 2004-03-25 Sepracor, Inc. TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE
JP4610336B2 (ja) 2002-09-16 2011-01-12 セプラコール インク． トランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミン及びそのホルムアミドによる中枢神経系障害の治療
EP1558231A4 (en) 2002-10-03 2010-09-08 Cypress Bioscience Inc DOSAGE CLIMBING AND FRICTIONAL DAILY DOSE OF ANTIDEPRESSANTS TO TREAT NEUROLOGICAL DISORDERS
GB0222912D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
GB0222909D0 (en) 2002-10-03 2002-11-13 Astrazeneca Ab Novel process and intermediates
US20040097554A1 (en) 2002-10-30 2004-05-20 Pfizer Inc Heteroaryl-hexanoic acid amide derivatives as immonomodulatory agents
CA2503727A1 (en) 2002-11-07 2004-05-21 Pfizer Products Inc. Anti-diabetic agents
JP4184378B2 (ja) 2003-01-31 2008-11-19 株式会社三和化学研究所 ジペプチジルペプチダーゼｉｖを阻害する化合物
ATE482747T1 (de) 2003-04-11 2010-10-15 High Point Pharmaceuticals Llc Neue amide derivate und deren pharmazeutische verwendungen
WO2004096768A1 (en) 2003-04-30 2004-11-11 Pfizer Products Inc. Anti-diabetic agents
WO2004113345A1 (ja) 2003-06-20 2004-12-29 Japan Tobacco Inc. 縮合ピロール化合物及びその医薬用途
SI1362864T1 (sl) 2003-06-30 2007-08-31 Servier Lab Nov postopek za sintezo perindoprila in njegovih farmacevtsko sprejemljivih soli
AU2004255863A1 (en) 2003-07-07 2005-01-20 Ciba Specialty Chemicals Holding Inc. Process for the preparation of furopyrroles
AU2004289174B2 (en) 2003-07-29 2011-05-19 Signature R&D Holdings, Lcc Amino acid prodrugs
US20050065183A1 (en) 2003-07-31 2005-03-24 Indranil Nandi Fexofenadine composition and process for preparing
WO2005020986A1 (en) 2003-08-29 2005-03-10 Astrazeneca Ab Heterocyclic amide derivatives which posses glycogen phosphorylase inhibitory activity
GB0320422D0 (en) 2003-08-30 2003-10-01 Astrazeneca Ab Chemical compounds
US7396940B2 (en) 2003-10-23 2008-07-08 Hoffmann-La Roche Inc. Combinatorial library of 3-aryl-1H-indole-2-carboxylic acid
DE60311942T2 (de) 2003-11-19 2007-12-06 Les Laboratoires Servier Verfahren für die Synthese von Perindopril und seiner pharmazeutischen annehmbaren Salzen
CN101798291A (zh) 2003-12-29 2010-08-11 塞普拉科公司 苯并[d]异噁唑-3-醇DAAO抑制剂
AU2004312530A1 (en) 2003-12-29 2005-07-21 Sepracor Inc. Pyrrole and pyrazole DAAO inhibitors
CA2559105A1 (en) 2004-03-16 2005-09-29 Janssen Pharmaceutica N.V. Benzisoxazoles
ES2346665T3 (es) 2004-05-07 2010-10-19 Warner-Lambert Company Llc Derivados de fenol y tiofenol 3- o 4-monosustituidos utiles como ligandos de h3.
WO2006001958A2 (en) 2004-05-21 2006-01-05 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
RU2361872C2 (ru) 2004-05-26 2009-07-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Циннамидное соединение
WO2005123677A1 (en) 2004-06-16 2005-12-29 Actelion Pharmaceuticals Ltd 4-carbonyl substituted 1,1,2-trimethyl-1a,4,5,5a-tetrahydro-1h-4-aza-cyclopropa'a!pentalene derivatives as agonists for the g-protein-coupled receptor s1p1/edg1 and immunosuppressive agents
WO2006004040A1 (ja) 2004-07-01 2006-01-12 Daiichi Asubio Pharma Co., Ltd. Ｐｄｅ７阻害作用を有するチエノピラゾール誘導体
US7276631B2 (en) 2004-07-20 2007-10-02 Bristol-Myers Squibb Company Cyclopentylamine and cyclohexylamine derivatives as NK-1/SSRI antagonists
JO2629B1 (en) 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
CA2594665A1 (en) 2005-01-19 2006-07-27 Biolipox Ab Thienopyrroles useful in the treatment of inflammation
CN100391945C (zh) 2005-05-31 2008-06-04 浙江大学 一种s-(-)-吲哚啉-2-羧酸的合成方法
US20090306169A1 (en) 2005-10-06 2009-12-10 Brandish Philip E Use of Fused Pyrrole Carboxylic Acids for the Treatment of Neurodegenerative and Psychiatric Diseases and D-Amino Acid Oxidase Inhibitors
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
BRPI0706365A2 (pt) 2006-01-06 2011-03-22 Sepracor Inc Cicloalquilaminas como inibidores da recaptação de monoamina
NZ569608A (en) 2006-01-06 2011-09-30 Sepracor Inc Tetralone-based monoamine reuptake inhibitors
DK2816024T3 (en) 2006-03-31 2017-10-30 Sunovion Pharmaceuticals Inc CHIRALE AMINER
US7579370B2 (en) 2006-06-30 2009-08-25 Sepracor Inc. Fused heterocycles
EP2057162A2 (en) 2006-06-30 2009-05-13 Sepracor Inc. Fused heterocyclic inhibitors of d-amino acid oxidase
US20080058395A1 (en) 2006-06-30 2008-03-06 Sepracor Inc. Fused heterocyclic inhibitors of D-amino acid oxidase
US7884124B2 (en) 2006-06-30 2011-02-08 Sepracor Inc. Fluoro-substituted inhibitors of D-amino acid oxidase
CN1962656A (zh) 2006-11-29 2007-05-16 沈阳药科大学 吲哚美辛5－氟尿嘧啶甲酯药用化合物及其制剂和制备方法
US20090099248A1 (en) 2007-01-18 2009-04-16 Sepracor Inc. Inhibitors of d-amino acid oxidase
US7902252B2 (en) 2007-01-18 2011-03-08 Sepracor, Inc. Inhibitors of D-amino acid oxidase
AU2008259841B2 (en) 2007-05-31 2015-02-05 Sunovion Pharmaceuticals Inc. Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
WO2010017418A1 (en) 2008-08-07 2010-02-11 Sepracor Inc. Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase

Also Published As

Publication number Publication date
RU2009110913A (ru) 2010-09-27
IL176606A0 (en) 2006-10-31
NZ548212A (en) 2010-07-30
US20090170916A1 (en) 2009-07-02
JP2007517056A (ja) 2007-06-28
CZ2006427A3 (cs) 2006-11-15
CN1922149A (zh) 2007-02-28
KR20060128976A (ko) 2006-12-14
RU2009110914A (ru) 2010-09-27
US20110092559A1 (en) 2011-04-21
WO2005066135A2 (en) 2005-07-21
RU2006127440A (ru) 2008-02-10
ZA200605383B (en) 2008-06-25
US7488747B2 (en) 2009-02-10
US20100016397A1 (en) 2010-01-21
WO2005066135A3 (en) 2005-10-06
IL200842A0 (en) 2010-05-17
BRPI0418244A (pt) 2007-04-17
US7893098B2 (en) 2011-02-22
US20050143443A1 (en) 2005-06-30
US7615572B2 (en) 2009-11-10
PL380887A1 (pl) 2007-04-02
RU2361862C2 (ru) 2009-07-20
EP1709004A2 (en) 2006-10-11
CA2551952A1 (en) 2005-07-21

Similar Documents

Publication Publication Date Title
US7488747B2 (en) Pyrrole and pyrazole DAAO inhibitors
US7166725B2 (en) Benzo[d]isoxazol-3-ol DAAO inhibitors
US7579370B2 (en) Fused heterocycles
US7902252B2 (en) Inhibitors of D-amino acid oxidase
US20090099248A1 (en) Inhibitors of d-amino acid oxidase
US20080058395A1 (en) Fused heterocyclic inhibitors of D-amino acid oxidase
JP2009542683A (ja) Ｄ−アミノ酸オキシダーゼの縮合ヘテロ環式阻害剤
MXPA06007537A (es) Inhibidores de pirrol y pirazol de d-aminoacido-oxidasa (daao)
MXPA06007536A (en) Benzo[d]isoxazol-3-ol daao inhibitors

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE CO-INVENTOR TO READ HEFFERNAN, MICHELE AND FANG, Q. KEVIN AND HOPKINS, SETH AND CHYTIL, MILAN

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application